Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lone survivor

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Sep 27, 2021 11:14am

82 Views

Post# 33923863

RE:Lone survivor

Lmao at the narcissisim. You’re assuming no has sold. Your posts reflect what an idiot you are and the attachments issues you have. Seek therapy for your abandonment issues.

Or keep posting pics of daddy’s car lmao

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal